ethyl 3-(trifluoromethyl)phenylsulfanylacetate | 771545-94-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-(trifluoromethyl)phenylsulfanylacetate
• 英文别名: (3-trifluoromethyl-phenylsulfanyl)-acetic acid ethyl ester；ethyl 2-[3-(trifluoromethyl)phenyl]sulfanylacetate
• CAS: 771545-94-9
• 化学式: C₁₁H₁₁F₃O₂S
• mdl: MFCD11646589
• 分子量: 264.268
• InChiKey: IDSBLJUZMBWLLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 3-(trifluoromethyl)phenylsulfanylacetate 在 一水合肼 作用下， 生成 (3-Trifluoromethyl-phenylsulfanyl)-acetic acid hydrazide
  参考文献：
  名称：

  5-硝基-2-糠基芳基硫代乙酰肼和5-硝基-2-糠基芳基磺酰基乙酰肼的合成和抗菌活性。

  摘要：

  DOI：

  10.1021/jm00271a041
• 作为产物：
  描述：

  以 二甲基亚砜 为溶剂， 以66 %的产率得到ethyl 3-(trifluoromethyl)phenylsulfanylacetate
  参考文献：
  名称：

  一种无硫醇制备烷基芳基硫醚的路线

  摘要：

  大多数现有的烷基芳基硫醚的合成方法需要使用硫醇作为起始原料，这存在实际限制。二芳基碘鎓盐与黄原盐（很容易由相应的醇和CS 2制备）在开发的条件下的反应代表了一种操作简单、无硫醇的合成这些有价值的化合物的方法。该方案具有高官能团耐受性，可应用于后期 C-H 官能化和 CD 3 S 基团的引入。

  DOI：

  10.1021/acs.joc.3c00734

文献信息

• Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1464335A3

  公开（公告）日：2007-05-09

  The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  这项发明涉及式(I)的化合物 其中Q是： 这些化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的使用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食障碍，包括暴食症、厌食症、精神障碍，包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍，包括帕金森病、癫痫和成瘾症。
• Modular Synthesis of Carbon-Substituted Furoxans via Radical Addition Pathway. Useful Tool for Transformation of Aliphatic Carboxylic Acids Based on “Build-and-Scrap” Strategy
  作者：Ryosuke Matsubara、Hojin Kim、Takaya Sakaguchi、Weibin Xie、Xufeng Zhao、Yuto Nagoshi、Chaoyu Wang、Masahiro Tateiwa、Akihiro Ando、Masahiko Hayashi、Masahiro Yamanaka、Takao Tsuneda

  DOI：10.1021/acs.orglett.0c00062

  日期：2020.2.7

  Utilizing radical chemistry, a new general C-C bond formation on the furoxan ring was developed. By taking advantage of the lability of furoxans, a wide variety of transformation of the synthesized furoxans have been demonstrated. Thus, this developed methodology enabled not only the modular synthesis of furoxans but also short-step transformations of carboxylic acids to a broad range of functional

  利用自由基化学，开发了在呋喃环上形成新的一般CC键的方法。通过利用呋喃喃的不稳定性，已证明了合成呋喃烷的多种转化。因此，这种发达的方法学不仅使呋喃喃的模块合成成为可能，而且使羧酸能够短时转化为各种官能团。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1464335A2

  公开（公告）日：2004-10-06

  The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及式（I）化合物 其中 Q 为 作为 MCH 受体拮抗剂的化合物。这些组合物可用于药物组合物中，其用途包括预防或治疗改善记忆功能、睡眠和唤醒、焦虑、抑郁、情绪障碍、癫痫发作、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴饮暴食症（包括贪食症）、厌食症、心肌梗塞、暴食症（包括贪食症）、厌食症、精神障碍（包括躁狂抑郁症）、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、药物滥用障碍和运动障碍（包括帕金森病）、癫痫和成瘾。
• [EN] NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF<br/>[FR] NOUVEAUX DERIVES QUINOLINE, TETRAHYDROQUINAZOLINE ET PYRIMIDINE, PROCEDES DE TRAITEMENT EN LIAISON AVEC L'UTILISATION DE CES DERNIERS
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004087669A1

  公开（公告）日：2004-10-14

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.